Baxter, Inc / Hospira UK Limited鈥檚 compounding business and related assets merger inquiry
The CMA investigated and cleared the anticipated acquisition by Baxter, Inc of Hospira UK Limited鈥檚 鈥榗ompounding鈥� business and related assets. Compounding is the process of combining, mixing or altering ingredients to create a medication.
Statutory timetable
| Phase 1 date | Action |
|---|---|
| 13 December 2018 | Decision announced |
| 18 October to 1 November 2018 | Invitation to comment |
| 18 October 2018 | Launch of merger inquiry |
Phase 1
CMA clearance decision
13 December 2018: The CMA has cleared the anticipated acquisition by Baxter International, Inc. of Hospira UK Limited鈥檚 compounding business and related assets.
- (4.1.19)
Invitation to comment: Now closed
18 October 2018: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
Launch of merger inquiry
18 October 2018: The CMA announced the launch of its merger inquiry by notice to the parties.
- (18.10.18)
Contact
Please send written representations about any competition issues to:
Updates to this page
-
Clearance decision announced.
-
First published.